Sichuan Kelun-Biotech Biopharmaceutical reported FY 2025 first half revenues of C¥950.4 million, with a basic EPS loss of C¥0.64. Revenue decreased significantly from C¥1.38 billion in 1H 2024 but showed a recovery from C¥550.3 million in 2H 2024. Despite a narrowing net loss from C¥576.99 million to C¥145.18 million, trailing twelve-month net income still reflects a loss of C¥381.97 million. The company’s revenue growth rate stands at 31.7% annually, outpacing the market, though ongoing losses raise concerns among investors about its high P/S ratio of 42x compared to peers. Investors will be monitoring whether this revenue growth translates into sustainable profits moving forward.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelunbiotech-sehk6990-losses-narrow-in-1h-2025-chall
